Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain ...

Dr Reddy's Laboratories on Thursday said it has joined hands with global biotech firm Alvotech to co-develop and commercialise a biosimilar product for treating multiple types of cancer. The Hyderabad ...

Alvotech focuses on biosimilars, aiming to lower healthcare costs amid rising drug prices and regulatory pressure against price hikes. Alvotech's aggressive market expansion shows promise with ...

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines ...

Alvotech has a current portfolio of eight products and product candidates targeting autoimmune disease, eye disorders, respiratory disease, and cancer. The company has successfully launched its ...

Alvotech, a biotech firm focused on biosimilar medicine development, announced the acquisition of Xbrane Biopharma’s R&D operations and a biosimilar candidate named XB003, aimed at extending its ...

REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”) has completed a private placement of the equivalent of 7,500,000 shares in Swedish Depository ...

Alvotech, a global biotech company focused on developing biosimilar medicines, announced that its stock will be included in the Nasdaq Biotechnology Index (NBI) as part of the index's annual ...

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to co-develop and commercialize a biosimilar of Merck's (NYSE:MRK) cancer drug ...